title: Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin.
abstract: We performed a 5-year retrospective study to evaluate the effect of long-term administration of norfloxacin on the epidemiology of severe hospital-acquired infections in patients with advanced cirrhosis. Sixty-seven episodes of spontaneous bacterial peritonitis and 60 episodes of bacteremia occurred in, respectively, 46 patients (group 1a) and 52 patients (group 1b) who did not receive norfloxacin, while 23 and 17 episodes occurred in 21 patients (group 2a) and 17 patients (group 2b) during or within 10 days after long-term administration of norfloxacin. Enterobacteriaceae were more prevalent in groups 1a and 1b than in the other two groups (P < .001 and P < .01, respectively); conversely, staphylococci were more prevalent in groups 2a and 2b (P < .001 and P < .05, respectively). The rate of staphylococcal resistance to methicillin was 53.6% in groups 1a and 1b and 77.3% in groups 2a and 2b. We conclude that long-term norfloxacin administration to cirrhotic patients reduces the risk of gram-negative infections but increases the risk of severe hospital-acquired staphylococcal infections and of high-level resistance to antibiotics.
authors.affiliation: Service d'Hépato-Gastro-Entérologie et Rééducation Digestive and Laboratoire de Bactériologie, Hôpital Albert Chenevier, Creteil, France.
authors.forename: B
authors.initials: B
authors.lastname: Campillo
authors.forename: C
authors.initials: C
authors.lastname: Dupeyron
authors.forename: J P
authors.initials: JP
authors.lastname: Richardet
authors.forename: N
authors.initials: N
authors.lastname: Mangeney
authors.forename: G
authors.initials: G
authors.lastname: Leluan
mesh_terms: D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis / Q000009:adverse effects; D001202:Ascitic Fluid / Q000382:microbiology; D016470:Bacteremia / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D003428:Cross Infection / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects / Q000302:isolation & purification; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications* / Q000188:drug therapy; D008137:Longitudinal Studies; D008297:Male; D016106:Methicillin Resistance; D008875:Middle Aged; D009643:Norfloxacin / Q000627:therapeutic use*; D010538:Peritonitis / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D012189:Retrospective Studies; D013210:Staphylococcus / Q000187:drug effects / Q000302:isolation & purification
chemical_list: D000890:Anti-Infective Agents; D009643:Norfloxacin